Biologics
Phase 3 results announced for Imfinzi plus Imdelltra in extensive-stage small cell lung cancer
Around 195,000 people globally will be treated for this form of lung cancer in 2026
Bristol Myers Squibb announces new $2.3bn campus in the US
Texas has been chosen as the site for a new, state-of-the-art multi-modal manufacturing campus
Genentech increases investment to $2bn for US manufacturing site
Roche and Genentech have a current commitment of $50bn for US manufacturing
Amgen agrees to lower prescription drug costs in deal with US government
The company has invested $40bn in US R&D and manufacturing in the past seven years
Amgen reports positive results from landmark cardiovascular study
The study found significant reductions of major cardiovascular events in high-risk adults following treatment
Lilly to invest $1.2bn in Puerto Rico manufacturing site
The investment will strengthen Lilly’s US manufacturing network
Amgen commits $650m to US manufacturing expansion
The investment is expected to generate up to 750 new jobs
Amgen and Kyowa Kirin announce rocatinlimab results for atopic dermatitis
The phase 3 study included around 2,600 patients
Amgen’s bemarituzumab shows promise in phase 3 gastric cancer study
Almost one million new cases of gastric cancer are diagnosed globally every year
Roche to boost US footprint with $50bn investment over next five years
The commitment is aimed at bolstering the company’s pharmaceutical and diagnostics divisions
Amgen’s Uplizna approved by FDA as first treatment for rare disease IgG4-RD
Immunoglobulin G4-related disease affects approximately 20,000 people in the US
Johnson & Johnson to invest more than $55bn in US over next four years
The commitment marks a 25% increase to the company's US investments in the past four years